BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 38282471)

  • 1. Recent progress in mRNA cancer vaccines.
    Yao R; Xie C; Xia X
    Hum Vaccin Immunother; 2024 Dec; 20(1):2307187. PubMed ID: 38282471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mRNA vaccines and their delivery strategies: A journey from infectious diseases to cancer.
    Malla R; Srilatha M; Farran B; Nagaraju GP
    Mol Ther; 2024 Jan; 32(1):13-31. PubMed ID: 37919901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA vaccines for cancer immunotherapy.
    Vishweshwaraiah YL; Dokholyan NV
    Front Immunol; 2022; 13():1029069. PubMed ID: 36591226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities.
    Wang B; Pei J; Xu S; Liu J; Yu J
    Front Immunol; 2023; 14():1246682. PubMed ID: 37744371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma.
    Grabbe S; Haas H; Diken M; Kranz LM; Langguth P; Sahin U
    Nanomedicine (Lond); 2016 Oct; 11(20):2723-2734. PubMed ID: 27700619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging advances in delivery systems for mRNA cancer vaccines.
    Jiang Z; Xu Y; Du G; Sun X
    J Control Release; 2024 Jun; 370():287-301. PubMed ID: 38679162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and immunological effects of mRNA vaccines in malignant diseases.
    Heine A; Juranek S; Brossart P
    Mol Cancer; 2021 Mar; 20(1):52. PubMed ID: 33722265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Building a Better Silver Bullet: Current Status and Perspectives of Non-Viral Vectors for mRNA Vaccines.
    Gu J; Xu Z; Liu Q; Tang S; Zhang W; Xie S; Chen X; Chen J; Yong KT; Yang C; Xu G
    Adv Healthc Mater; 2024 Jan; 13(3):e2302409. PubMed ID: 37964681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
    Qiu M; Li Y; Bloomer H; Xu Q
    Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of alternative splicing-derived cancer neoantigens for mRNA vaccine development.
    Cheng R; Xu Z; Luo M; Wang P; Cao H; Jin X; Zhou W; Xiao L; Jiang Q
    Brief Bioinform; 2022 Mar; 23(2):. PubMed ID: 35279714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA Cancer Vaccines.
    Fiedler K; Lazzaro S; Lutz J; Rauch S; Heidenreich R
    Recent Results Cancer Res; 2016; 209():61-85. PubMed ID: 28101688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mRNA vaccine for cancer immunotherapy.
    Miao L; Zhang Y; Huang L
    Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mRNA Cancer Vaccines: Construction and Boosting Strategies.
    Liu X; Huang P; Yang R; Deng H
    ACS Nano; 2023 Oct; 17(20):19550-19580. PubMed ID: 37819640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond.
    Estapé Senti M; García Del Valle L; Schiffelers RM
    Adv Drug Deliv Rev; 2024 Mar; 206():115190. PubMed ID: 38307296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of mRNA therapies against solid tumors.
    Wu D; Hu L; Wang X; Yu Y; Jia SP; Huang HY; Li ZW; Ma JF; Zhu HB; Tang Y; Li N
    J Hematol Oncol; 2023 Jul; 16(1):75. PubMed ID: 37464375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Mannosylated Lipid Nanoparticles for mRNA Cancer Vaccine with High Antigen Presentation Efficiency and Immunomodulatory Capability.
    Lei J; Qi S; Yu X; Gao X; Yang K; Zhang X; Cheng M; Bai B; Feng Y; Lu M; Wang Y; Li H; Yu G
    Angew Chem Int Ed Engl; 2024 Mar; 63(13):e202318515. PubMed ID: 38320193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines.
    Guevara ML; Persano S; Persano F
    Curr Pharm Des; 2019; 25(13):1443-1454. PubMed ID: 31258071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.
    Oberli MA; Reichmuth AM; Dorkin JR; Mitchell MJ; Fenton OS; Jaklenec A; Anderson DG; Langer R; Blankschtein D
    Nano Lett; 2017 Mar; 17(3):1326-1335. PubMed ID: 28273716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
    Wang C; Zhang Y; Dong Y
    Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.